ABT vs MDT
ABT and MDT side by side — valuation & fundamentals (public data).
Key statistics
| Metric | ABTABBOTT LABORATORIES | MDTMedtronic plc |
|---|---|---|
| Market cap | $187.78B | $111.57B |
| P/E (TTM) | 30.2 | 23.4 |
| P/B | 3.61 | 2.26 |
| P/S | 4.2x | 3.1x |
| Dividend yield | 2.19% | 3.26% |
| Revenue | $45.13B(TTM) | $36.36B(TTM) |
| Revenue growth (YoY) | 5.7% | 8.4% |
| Net income | $6.28B(TTM) | $4.80B(TTM) |
| Earnings growth (YoY) | -51.3% | 3.0% |
| EPS, diluted | $3.57(TTM) | $3.73(TTM) |
| EBIT margin | 18.2% | 17.8% |
| ROE | 12.5% | 9.7% |
| ROIC | 8.3% | 7.1% |
| Piotroski F | — | 8/9 |
| 1y total return | -16.6% | -1.4% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: ABT vs MDT
| Metric | ABT | MDT |
|---|---|---|
| End value | $30.6K | $14.4K |
| Total return | +206.0% | +44.3% |
| CAGR | +11.4% | +3.6% |
| Volatility | 24.0% | 23.2% |
| Sharpe | 0.41 | 0.10 |
| Sortino | 0.58 | 0.14 |
| Max drawdown | -39.6% | -45.3% |
Based on 2600 common trading days, 2016-04-06 → 2026-08-07 · risk-free 3.87% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)